Addressing the global MS movement, Prof Mai Sharawy, Chair of the Board of Trustees of Multiple Sclerosis International Federation (MSIF), highlights the positive impact of the WHO’s decision and acknowledges the efforts made by member organisations and many others.
‘The inclusion of three disease-modifying therapies for MS in the essential medicines list (EML) by the World Health Organization (WHO) is a momentous decision that underscores pressing health challenges faced by people with MS and their carers worldwide and especially in countries where access to disease-modifying therapies is often limited or unavailable as shown in the Atlas of MS. ’
‘This inclusion will facilitate the procurement, availability, and affordability of these medicines and ultimately improve the health outcomes and quality of life of people with MS around the world. This achievement would not have been possible without the concerted and tireless efforts of MSIF member organizations, healthcare professionals, researchers in TRIMs and neurological organizations, people with MS, and dedicated individuals who worked together as a great team committed to improving global health.’
